Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Inovio Pharmaceuticals : Added to NASDAQ Biotechnology Index

12/15/2014 | 08:01am EDT

PLYMOUTH MEETING, Pa., Dec. 15, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today it has been added to the NASDAQ Biotechnology Index (NBI). The addition to the NASDAQ Biotechnology Index will become effective upon market open on December 22, 2014.

The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is re-ranked annually in December. The NASDAQ Biotechnology Index forms the basis for the iShares NASDAQ Biotechnology Index Fund (IBB) which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges. For more information about the NASDAQ Biotechnology Index visit:
https://indexes.nasdaqomx.com/Index/Overview/NBI.

Dr. J. Joseph Kim, President & CEO of Inovio, said, "This addition is another milestone for Inovio as we advance our DNA immunotherapies and vaccines. We're pleased to meet the criteria for inclusion into the most influential biotechnology index."

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include Roche, MedImmune, University of Pennsylvania, DARPA, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba. For more information, visit www.inovio.com.

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, including INO-5150, and to commence a phase I clinical trial for INO-5150 in the first half of 2015, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2013, our Form 10-Q for the quarter ended September 30, 2014, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

http://photos.prnewswire.com/prnvar/20131118/LA18202LOGO

Logo - http://photos.prnewswire.com/prnh/20131118/LA18202LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/inovio-pharmaceuticals-added-to-nasdaq-biotechnology-index-300009308.html

SOURCE Inovio Pharmaceuticals, Inc.


© PRNewswire 2014
All news about INOVIO PHARMACEUTICALS, INC.
10/12INOVIO PHARMACEUTICALS : Announces Online Preprint Publication of Homologous Boosting Data..
PR
10/12Inovio Pharmaceuticals, Inc. Announces Online Preprint Publication of Homologous Boosti..
CI
10/11INOVIO PHARMACEUTICALS : Secures Approval to Conduct Phase 3 Trial of COVID-19 DNA Vaccine..
MT
10/11INOVIO PHARMACEUTICALS : Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate ..
PR
10/11INOVIO Expands Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include..
CI
09/29INOVIO PHARMACEUTICALS : to Present Three Posters at IDWeek 2021
PR
09/22INOVIO PHARMACEUTICALS : Gets Approval from Mexico Regulator for COVID-19 Vaccine Efficacy..
MT
09/22INOVIO PHARMACEUTICALS : Receives Regulatory Authorization to Conduct Phase 3 Efficacy Tri..
PR
09/22INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID..
CI
09/10INOVIO PHARMACEUTICALS : BofA Securities Downgrades Inovio Pharmaceuticals to Underperform..
MT
More news
Analyst Recommendations on INOVIO PHARMACEUTICALS, INC.
More recommendations